Certain Balance Sheet Components - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Mar. 31, 2026 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Accumulated accrual contractual costs | $ 42,500 | $ 42,500 | $ 42,500 | ||
| Accrued compensation-related expenses | 22,900 | 22,900 | |||
| Research and development expenses | $ 145,747 | $ 164,568 | 347,763 | $ 317,487 | |
| Moderna | |||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| General and administrative expenses | 18,800 | ||||
| Research and development expenses | $ 4,100 | ||||
| X | ||||||||||
- Definition Accumulated Contractual Costs No definition available.
|
| X | ||||||||||
- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|